- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
- Life sciences and high technology expert will focus on investing at the intersection of healthcare and IT -
Dr. Andrey Zarur has joined Kodiak Venture Partners, a seed and early stage venture capital firm, as General Partner. Zarur will source deals and support Kodiak portfolio companies within the intersection of the healthcare and high technology markets.
Recent years have seen a significant market emerge as a result of the convergence of life sciences and information technology disciplines. Kodiak recognizes this fast-growing market as the evolution of traditional investment areas such as IT and IT-related software and services as they begin to propagate into the healthcare and medical devices markets. The concentration of world class academic centers and teaching hospitals, coupled with a fertile ground for new ventures in these segments, make the Greater Boston area especially attractive for investing in companies focusing on convergence of healthcare and IT. Kodiak has made two investments in this area, ALIS (acquired by Carl Zeiss SMT in July 2006) and Cambridge Devices.
"I am thrilled to join Kodiak and spearhead entry into this exciting market," said Zarur. "The firm's dedication to early stage investing, strong entrepreneurial focus and dynamic team position us for success."
Andrey Zarur, Ph.D., has over 15 years of operating and investing experience. He joins Kodiak from BioProcessors, where he was founder and CEO. Prior to BioProcessors, Zarur served as an executive, investor or board member of over ten startups in areas including bioinformatics, genomics, medical devices, nanotechnology-derived materials and energy systems. He currently serves on the scientific advisory boards of Anecova and StemLife, and serves on the boards of directors of BioProcessors and Cambridge Devices (a Kodiak portfolio company). Zarur is also a director of Infantia, a foundation that provides education and board to underprivileged children in developing countries.
Zarur has earned several prestigious academic and management awards, authored over 20 articles in peer-reviewed journals, counts over 100 issued and pending patents to his name, and lectures at the Sloan School of Management at the Massachusetts Institute of Technology (MIT). He earned a B.Sc. in chemical engineering from the National University of Mexico, and a M.Sc.B. and a Ph.D. in chemical engineering from MIT.
"We have seen the evolution of the IT market over the past few funds, and decided to evolve with it by adding these converging disciplines into our investing focus," said Lou Volpe, Managing General Partner, Kodiak Venture Partners. "We have known and interacted with Andrey for several years and view him as the perfect complement to the Kodiak team—he brings the operational and technological expertise, and hands-on approach of all our partners into investments in these areas."
About Kodiak Venture Partners
Kodiak Venture Partners is a Waltham, Mass.-based venture capital firm focused on seed and early stage investments in emerging communications/wireless, semiconductor/equipment, software/services and Internet/new media companies. With a focus in the eastern regions of the U.S. and Canada, Kodiak establishes relationships with entrepreneurs seeking market success. Kodiak’s investment partners are successful high-technology business entrepreneurs who take a hands-on approach to building market leaders.
For more information, please click here
Vicki Sakakeeny, 011 506 342 3877
Kodiak Venture Partners
Liz Neal, 781-684-0222
Copyright © Business WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
PEN Inc. Announces 1-for-180 Reverse Stock Split January 27th, 2016
Creating a color printer that uses a colorless, non-toxic ink inspired by nature February 11th, 2016
SLAC X-ray laser turns crystal imperfections into better images of important biomolecules: New method could remove major obstacles to studying structures of complex biological machines February 11th, 2016
Nanoparticle reduces targeted cancer drug's toxicity February 11th, 2016
Cima NanoTech Debuts Large Interactive Touch Screens with European Customers at ISE 2016: For the first time in Europe, Cima NanoTech’s wide range of high performance, projected capacitive touch modules are showcased February 11th, 2016
Semblant Appoints Donald Cunningham as Chief Commercial Officer January 2nd, 2016